Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

Fred Saada Department of Urology, University of Montreal Hospital Center, Montreal, QC, CanadaCorrespondence[email protected]

Andrew Chilellib HEOR Oncology, Astellas Pharma, Markham, ON, Canada

Benny Huib HEOR Oncology, Astellas Pharma, Markham, ON, Canada

Sergey Muratovc IQVIA, Kirkland, QC, Canada;d Department of Health Research Methods, Evidence, and Impact, McMaster University, Faculty of Health Sciences, Hamilton, ON, Canada

Arijit Gangulie HEOR Oncology, Astellas Pharma Inc, Northbrook, USA

Scott Northf Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Bobby Shayegang St. Joseph’s Healthcare, McMaster University, Institute of Urology, Hamilton, ON, Canada

show all

Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date